Gilead Sciences’ new HIV therapeutic Biktarvy has recently gained approval, and is expected to have a major impact on the market.

The drug is a combination anti-retroviral therapy made up of the novel integrase inhibitor bictegravir, alongside Gilead’s already marketed combo therapy Descovy, which consists of emtricitabine and tenofovir alafenamide.

Descovy is already a blockbuster drug, with revenue of $1.2 billion in 2017, and this has led to expectations that Biktarvy will have a similar impact on the market.

Each of the drugs in the combination works through a different mechanism to create a synergistic effect that prevents the HIV virus from replicating within the host cell, and also works to prevent it from spreading.

Strong enough to succeed

Biktarvy faces direct competition from GlaxoSmithKline’s already marketed dual therapy Juluca.

This was a breakthrough treatment due to it being the first complete treatment containing only two therapeutics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, the strong clinical trial data that Biktarvy has displayed has led to confidence that it will succeed for Gilead, and become another strong part of its therapeutic portfolio.

GBI Research expects sales of $754m in 2018 alone, with revenue expected to reach $5.4 billion by 2023, making it Gilead’s most lucrative drug over the coming years.

For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.